anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and system for predicting liver injury in vivo due to hepatocyte damage by a test compound are provided. The method includes acquiring images of fluorescently stained cells obtained from a cell culture in which the cells have been treated with a dose-range of at least the test compound and its vehicle. The cells may be hepatic cells including primary or immortalized hepatocytes, hepatoma cells or induced pluripotent stem cell-derived hepatocyte-like cells. The acquired images are segmented. The method further includes extracting and analyzing one or more phenotypic features from the segmented images, wherein the one or more phenotypic features are selected from the group of intensity, textural, morphological, or ratiometric features consisting of (a) features of DNA, (b) features of RELA (NF-KB p65), and (c) features of actin filaments at different subcellular regions and d) features of cellular organelles and their substructures in the segmented images. Finally, the method includes normalizing results from the treated samples to vehicle controls and predicting the probability of liver injury by the test compound based on test compound-induced normalized changes of the extracted and selected phenotypic features using machine learning methods.
The efficacy of NICOTROL NS therapy as an aid to smoking cessation was demonstrated in three single-center, placebo-controlled, double-blind trials with a total of 730 patients. One of the trials used NICOTROL NS with individual counseling while the other two used group support. Patients with severe or symptomatic cardiovascular disease, hypertension, asthma, diabetes or severe allergy were not included in the studies. The amount of NICOTROL NS used was left to the discretion of each patient, with a minimum dose of 8 mg/day and a maximum dose of 40 mg/day.

In all three studies, the recommended duration of treatment was 3 months; however in two of these trials, 241 patients were permitted to continue to use the product for up to 1 year, if they wished. Among the 64 patients abstinent from cigarettes at the end of a year, 23 (36%) were still using the spray, and probable dependence on the spray was seen in several patients (See DRUG ABUSE AND DEPENDENCE).

Quitting was defined as total abstinence from smoking for at least 4 weeks. The "quit rates" are the percentage of all persons initially enrolled who continuously abstained after week 2 or 4.

In all three studies, NICOTROL NS was more effective than placebo at 6 weeks, 3 months, 6 months, and 1 year. The two studies where NICOTROL NS could be used for more than 6 months did not have a better outcome at 1 year than the study in which NICOTROL NS was discontinued at 6 months.

Patients treated with NICOTROL NS had more relief of the urge to smoke and withdrawal symptoms compared with placebo-treated patients.

NICOTROL NS allows the patient to vary the dose of nicotine on a short-term basis. As with other variable dose smoking cessation products, NICOTROL NS may be useful in the management of highly dependent smokers.
The intervention, "Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer," is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment.
The human 16p11.2 chromosomal region is rich in segmental duplications which mediate the formation of recurrent CNVs. CNVs affecting the 16p11.2 region are associated with an increased risk for developing neuropsychiatric disorders, including autism spectrum disorder (ASD), schizophrenia, and intellectual disability (ID), as well as abnormal body weight and head circumference and dysmorphic features, with marked phenotypic variability and reduced penetrance. CNVs affecting the 16p11.2 region mainly affect a distal interval of ~220 Kb, between Breakpoints 2 and 3 (BP2-BP3), and a proximal interval of ~593 Kb (BP4-BP5). Here, we report on 15 patients with recurrent 16p11.2 rearrangements that were identified among a cohort of 1600 patients (0.9%) with neurodevelopmental disorders. A total of 13 deletions and two duplications were identified, of which eight deletions included the proximal 16p11.2 region (BP4-BP5) and five included the distal 16p11.2 region (BP2-BP3). Of the two duplications that were identified, one affected the proximal and one the distal 16p11.2 region; however, both patients had additional CNVs contributing to phenotypic severity. The features observed and their severity varied greatly, even between patients within the same family. This article aims to further delineate the clinical spectrum of patients with 16p11.2 recurrent rearrangements in order to aid the counselling of patients and their families.
Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue to receive treatment at the discretion of the treating physician.
Additionally two reference databases, established during previous research, will be used to improve interpretation. A normative reference database of typically developing children will be used to calculate the three-dimensional gait analysis outcomes. This database consists of 87 typically developing children (aged between 4,5 and 18,5 years, 42 boys and 45 girls, weight range 17,6 and 92,5 kg, height range between 1,08 and 1,9 meter). A reference database of children with spastic CP without a SDR intervention will be used to qualitatively judge the muscle morphology of children with spastic CP with an SDR intervention. This database consists of 206 children with CP (aged between 0,6 and 17,4 years, 124 boys and 82 girls, weight range 5,8 and 82,0 kg, height range between 0,6 and 1,9 meter, 88 with unilateral and 118 with bilateral involvement, 104 with a GMFCS level 1, 63 with a level 2 and 39 with a level 3).
Infants undergoing routine eye screening at Edinburgh Royal Infirmary Neonatal Intensive Care Unit are to be recruited. Infants will be excluded if they require mechanical ventilation or analgesic medication or if they have moderate/severe neurological impairment. The first screening examination for each baby was included. Infants' eyes will be examined by both WFDRI and BIO with eyelid speculum by 2 experienced pediatric ophthalmologists in random order. Observations will be video-recorded during examinations to generate a pain score (premature infant pain profile) for both WFDRI and BIO. The pain scores, heart rates, oxygen saturations and time taken for WFDRI and BIO will be compared using paired t tests.
The present invention relates to a composition for preventing and alleviating diabetes, the composition comprising a Porostereum sp. (KCTC18837P) mycelium culture as an active ingredient. The Porostereum sp. (KCTC18837P) mycelium culture contains a lot of active ingredients such as inorganic ingredients, amino acids, vitamins, and the like in addition to beta-glucan and extracellular polysaccharide effective for antidiabetics. It was confirmed that these cultures are safe as natural materials and have excellent antidiabetic effects. Accordingly, the Porostereum sp. (KCTC18837P) mycelium culture of the present invention is expected to be useful for the prevention and alleviation of diabetes.
BACKGROUND: Identification of reliable biomarkers to assess kidney fibrosis severity is necessary for patients with CKD. Activin A, a member of the TGF- β superfamily, has been suggested as a biomarker for kidney fibrosis. However, its precise utility in this regard remains to be established.
METHODS: We investigated the correlation between plasma activin A levels, kidney fibrosis severity, and the incidence of major adverse kidney events in patients who underwent native kidney biopsies at a tertiary medical center. We performed RNA sequencing and histological analyses on kidney biopsy specimens to assess activin A expression. In vitro experiments were also conducted to explore the potential attenuation of TGF- β -induced fibroblast activation through activin A inhibition.
RESULTS: A total of 339 patients with biopsy-confirmed kidney diseases were enrolled. Baseline eGFR was 36 ml/min per 1.73 m 2 , and the urine protein/creatinine ratio was 2.9 mg/mg. Multivariable logistic regression analysis revealed a significant association between plasma activin A levels and the extent of tubulointerstitial fibrosis. Our RNA sequencing data demonstrated a positive correlation between kidney INHBA expression and plasma activin A levels. Furthermore, the histological analysis showed that myofibroblasts were the primary activin A-positive interstitial cells in diseased kidneys. During a median follow-up of 22 months, 113 participants experienced major adverse kidney events. Cox proportional hazards analysis initially found a positive association between plasma activin A levels and kidney event risk, but it became insignificant after adjusting for confounders. In cultured fibroblasts, knockdown of activin A significantly attenuated TGF- β -induced fibroblast-myofibroblast conversion.
CONCLUSIONS: Plasma activin A levels correlate with kidney fibrosis severity and adverse outcomes in various kidney disorders.
Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
Caution should be taken in concurrent or serial use of other neurotoxic and/or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin (see boxed WARNINGS) . 

Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin's nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate's neuromuscular blocking effects.

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. The gastrointestinal absorption of digoxin also appears to be inhibited. Therefore, digoxin serum levels should be monitored.

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
Embodiments are directed to monitoring communication over a network using a network monitoring computer (NMC). If one or more flows include healthcare traffic provided by one or more healthcare services, the NMC may perform further actions. Healthcare values from the one or more healthcare services may be provided from the network traffic. Values from one or more network traffic flows that are separate from the healthcare traffic may be provided. Other healthcare values from other flows may be provided that include healthcare traffic provided by the healthcare services. Accordingly, if a comparison of the healthcare values and the other healthcare values meet certain conditions, additional actions may be performed based on rules, or policies. The healthcare traffic may be compliant with one or more of Health Level Seven (HL7) standard, Digital Imaging and Communications in Medicine (DICOM) standard, or the like.
<P>PROBLEM TO BE SOLVED: To provide a use of a cosmetic composition comprising, in a cosmetically acceptable medium, at least one organic compound containing silicon atoms in combination with a composition for treating and/or washing keratinous fibers such as hair.  <P>SOLUTION: At least one organic compound containing silicon atoms in a cosmetically acceptable medium is used in combination with a composition for treating and/or washing keratinous fibers, particularly human keratinous fibers, e.g. hair. A method of cosmetic treatment of keratinous fibers, particularly human keratinous fibers, e.g. hair, comprises applying a cosmetic composition comprising, in a cosmetically acceptable medium, at least one organic compound containing silicon atoms in combination with a treating and/or washing composition.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention relates to a strain having an excellent glutathione- producing ability. As such, provided are a novel yeast strain producing glutathione and a method of producing glutathione using the same. The novel yeast strain includes a Saccharomyces cerevisiae strain. The method of producing glutathione using said strain includes the steps of culturing the strain, and mixing an additive with one or more materials selected from the cultured strain, a dry product of the strain, an extract of the strain, a culture of the strain, a lysate of the strain, and glutathione collected therefrom. The strain of the present invention can produce a significantly large amount of glutathione compared to existing glutathione-producing strains. Therefore, the strain of the present disclosure can be effectively used for the preparation of glutathione. (Figure 1)
The HPI-group will have the HPI based monitoring with the Acumen IQ sensor (Edwards Lifesciences) and the HPI algorithm connected also to the HemoSphere platform (Edwards Lifesciences). The hemodynamic management will be based on the HPI indications and the specific algorithm, which considers hypovolemia, impaired contractility and vasodilatation. An alert pops up on the monitor screen when the HPI values exceeds 85 and then the clinician needs to make therapeutic decision in order to avoid the hypotensive episode.
For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily \[od\] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum \[ac\] before meals).
FIELD: data processing devices of various types.SUBSTANCE: method involves combining two or more depersonalized health databases (X, Y). Each depersonalized health database has personal data which are not identified, including by replacing medical institutions with aggregates for medical institutions. When combining databases, statistical distribution of patient characteristics is calculated for aggregates for medical institutions in anonymous health databases. Fillers for medical institutions in different impersonal health databases are compared by matching the corresponding statistical distribution of patient characteristics for the respective aggregates for medical institutions. Patients in different depersonalized health databases are compared by comparing the matched pairs of aggregates for the respective medical institutions, which increases efficiency of calculations. Forming a database matching table (16) identifying the matched patients, or forming a combined depersonalized health database, which combines patient characteristics in different impersonal health databases for each mapped patient into a single patient record taking into account medical facilities.EFFECT: technical result is faster processing and security of data.20 cl, 4 dwg
BACKGROUND: Patellar tendon rupture (PTR) is extremely rare but serious complication after primary or revision total knee arthroplasty. Due to the serious failure rates of end-to-end repair techniques, various augmentation techniques have been described. In this study, the results of patients with PTR after reconstruction using our own technique with semitendinosus (ST) and gracilis tendons taken from the affected side were evaluated retrospectively.
METHODS: A total of 14 patients, whose diagnosis was made based on physical examination and clinical findings, and supported radiologically (ultrasonography), were included in the study. In these patients, reconstruction was performed using double-row repair technique with the ST and gracilis tendons. Active-passive knee joint range of motion, active knee extension loss, and the Caton-Deschamps index at preoperative and final follow-up visits were compared. Tegner-Lysholm knee score and Kujala score were used to evaluate functional results.
RESULTS: In 14 patients (8 women and 6 men) with a mean age of 68.1 years, the median time between injury and surgery was 6.6 weeks. In all patients, the rupture was in the distal part of the patellar tendon. While the median preoperative Caton-Deschamps index was 1.8, the postoperative median value was found to be 1.25 after an average follow-up of 3.8 years (P = .014). The median preoperative knee extension loss decreased from 25° to 5° postoperatively. Tegner-Lysholm knee score and Kujala score of the patients at their last follow-up were significantly increased (P < .01).
CONCLUSION: For PTR developing after total knee arthroplasty, the double-row reconstruction technique with ST and gracilis tendons is effective.
PURPOSE: A Hibiscus abelmoschus extract and Betula platyphylla var. japonica sap are provided to normalize expression of a gene of which expression is reduced by UV rays, to maintain homeostasis, and to effectively prevent aging. CONSTITUTION: A cosmetic composition for maintaining skin homeostasis contains one or more kinds from a Hibiscus abelmoschus extract and Betula platyphylla var. japonica sap as active ingredients. A cosmetic composition for improving skin elasticity contains one or more kinds from the Hibiscus abelmoschus extract and Betula platyphylla var. japonica sap as active ingredients. A cosmetic composition for antioxidation or antiaging contains one or more kinds from the Hibiscus abelmoschus extract and Betula platyphylla var. japonica sap as active ingredients. [Reference numerals] (AA) Bmal1 expression as compared with 0 hour, %; (BB) Time, h; (CC) UVB 20mJ Betula platyphylla var. japonica sap 50ppm; (DD) UVB 20mJ Hibiscus abelmoschus extract 100ppm
PURPOSE:An oil-containing powdery particles that are prepared by allowing petal-like silica of high oil absorption to absorb an hydrophobic oil or perform oil and coating the silica with a water-soluble polymer on their surfaces, thus showing high stability of the hydrophobic oil and sufficiently developing the properties of the oil, when it is applied. CONSTITUTION:A 100pts.wt. of petal-like silica is allowed to absorb 10-1,000pts. wt. of a variety of liquid or solid, hydrophobic oil such as avocado oil, vitamins, lanolin, fluid paraffin, vaseline, synthetic esters, silicone oil, jasmine oil or lavender oil and the resultant silica is coated with a water-soluble polymer such as polyvinyl alcohol, polyacrylamide, sodium alginate or arabic gum to give the objective oil-containing powdery particles. EFFECT:It can release uniformly oil or perfume, when it is dissolved in cold or hot water.
BACKGROUND: Both anastomotic leak (AL) and conduit necrosis (CN) after oesophagectomy are associated with high morbidity and mortality. Therefore, the identification of preoperative, modifiable risk factors is desirable. The aim of this study was to generate a risk scoring model for AL and CN after oesophagectomy.
METHODS: Patients undergoing curative resection for oesophageal cancer were identified from the international Oesophagogastric Anastomosis Audit (OGAA) from April 2018-December 2018. Definitions for AL and CN were those set out by the Oesophageal Complications Consensus Group. Univariate and multivariate analyses were performed to identify risk factors for both AL and CN. A risk score was then produced for both AL and CN using the derivation set, then internally validated using the validation set.
RESULTS: This study included 2247 oesophagectomies across 137 hospitals in 41 countries. The AL rate was 14.2% and CN rate was 2.7%. Preoperative factors that were independent predictors of AL were cardiovascular comorbidity and chronic obstructive pulmonary disease. The risk scoring model showed insufficient predictive ability in internal validation (area under the receiver-operating-characteristic curve [AUROC] = 0.618). Preoperative factors that were independent predictors of CN were: body mass index, Eastern Cooperative Oncology Group performance status, previous myocardial infarction and smoking history. These were converted into a risk-scoring model and internally validated using the validation set with an AUROC of 0.775.
CONCLUSION: Despite a large dataset, AL proves difficult to predict using preoperative factors. The risk-scoring model for CN provides an internally validated tool to estimate a patient's risk preoperatively.
FIELD: medicine, pharmaceutical technology, pharmacy. SUBSTANCE: invention relates to tablet with enterosoluble coating and method of its making. Tablet comprises medicinal agent exhibiting sensitivity to low values of medium pH lower 3, for example, 2',3'-dideoxyinosine, enterosoluble coating prepared from copolymer of methacrylic acid and plasticizer. Tablets can be made of different size and can be intaken orally singly; or multiple tablets to provide the required dose can be incapsulated into soluble capsule. Tablets exhibit excellent stability against decomposition at pH lower 3 and excellent properties providing release of medicinal substance at pH above 4.2. EFFECT: improved properties of tablet. 40 cl, 4 tbl
SUMOylation plays a crucial role in numerous cellular biological and pathophysiological processes associated with human disease; however, the mechanisms regulating the genes involved in SUMOylation remain unclear. In the present study, E2F transcription factor 4 (E2F4) was identified as an E2F member related to hepatocellular carcinoma (HCC) progression by public database analysis. It was found that E2F4 promoted the proliferation and invasiveness of HCC cells via SUMOylation using Soft agar and Transwell migration assays. Mechanistically, it was demonstrated that E2F4 upregulated the transcript and protein expression levels of baculoviral IAP repeat containing 5, cell division cycle associated 8 and DNA topoisomerase II α using western blotting. Furthermore, the interaction between E2F4 with lin‑9 DREAM multi‑vulva class B core complex component (LIN9) was explored by co‑immunoprecipitation, immunofluorescence co‑localization and bimolecular fluorescence complementation assays. Moreover, it was demonstrated that E2F4 promoted the progression of HCC cells via LIN9. Rescue experiments revealed that LIN9 facilitated the SUMOylation and proliferation of HCC cells, which was prevented by knocking down E2F4 expression. In conclusion, the findings of the present study indicated that E2F4 plays a major role in the proliferation of HCC cells and may be a potential therapeutic target in the future.
The invention provides a preparation method of a hemostatic anti-adhesion polypeptide hydrogel, the coagulation rate of the polypeptide self-assembled hydrogel is up to 99.11+/-0.66%, and the hemostatic polypeptide self-assembled hydrogel has excellent hemostatic performance. At the same time, the substitution of D-type amino acid does not cause a significant decrease in hemostatic performance. The polypeptide self-assembled hydrogel also has excellent anti-adhesion effect, and can be suitable for the treatment of postoperative wounds. The preparation method adopted by the invention has the advantages of simple system, rapid reaction and no need of adding auxiliary gelling factors. The self-assembled hydrogel prepared by the invention has good anti-adhesion activity and has a wide clinical application prospect. The preparation method adopted by the invention has simple system, rapid response and no need of adding auxiliary gelling factors, and has great clinical application prospect.